论文部分内容阅读
目的:分析华蟾素注射液致不良反应发生的原因,探讨合理用药对策。方法:利用《中国知网》、《万方数据医药信息系统》、《中文期刊数据库》等数据库,从2012年1月—2016年12月期间检索华蟾素注射液、不良反应等为关键词,共检索出63例患者因使用华蟾素注射液所致的不良反应文献,分析患者的年龄和不良反应类型以及发生时间,并提出合理用药对策。结果:63例华蟾素注射液致不良反应患者中,男性患者(占60.32%)明显多于女性为39.68%(P<0.05),患者年龄为18～45岁(占77.78%)明显高于其他年龄段病例(P<0.05);不良反应类型为过敏反应和发热反应的占第1、2位分别为49.21%和38.09%,偶见静脉炎、休克和白细胞计数减少;多次用药致不良反应的发生率为76.19%高于首次用药为7.94%(P<0.05);不良反应发生时间主要在给药2～3 d间(占41.27%)与给药4～10 d间(占49.21%)。结论:采用华蟾素注射液所致的不良反应类型主要为过敏和发热反应,未见死亡病例;临床中应对症处理不良反应,采取适当措施避免不良反应的发生。
Objective: To analyze the causes of adverse reactions caused by cinobufagin injection and to explore the rational use of drugs. Methods: The key words of cinobufacini injection and adverse reactions were retrieved from January 2012 to December 2016 using databases such as “CNKI”, “Wanfang Data Medical Information System” and “Chinese Journal Database” A total of 63 patients were retrospectively searched for adverse reactions caused by using cinobufacini injection. The patients’ ages, types of adverse reactions, and the timing of their occurrence were analyzed, and reasonable treatment strategies were proposed. Results: Among 63 cases of adverse reactions caused by cinobufotalin injection, the male patients (60.32%) were significantly more than the female patients (39.68%) (P <0.05), and the patients aged 18-45 years (77.78%) were significantly Other cases of age (P <0.05). Adverse reactions of type 1 and 2 were 49.21% and 38.09% respectively. Occasionally, phlebitis, shock and leukocyte count decreased. The incidence of adverse reactions was 76.19%, which was 7.94% (P <0.05) for the first time. The time of adverse reactions was mainly between 2 and 3 d (41.27%) and between 4 and 10 d (49.21% ). Conclusions: The adverse reactions induced by cinobufagin injection are mainly allergic and fever-free, and no deaths were observed. In the clinical treatment of adverse reactions, appropriate measures should be taken to avoid the occurrence of adverse reactions.